Oxidative Medicine and Cellular Longevity / 2020 / Article / Fig 5

Research Article

Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways

Figure 5

Trastuzumab in combination with brusatol effectively enhanced ROS accumulation in BT-474 and SK-OV-3 cells. (a) BT-474 were treated with control IgG (25 μg/mL), trastuzumab (25 μg/mL), brusatol (5 μM), or trastzumab (25 μg/mL) plus brusatol (5 μM) for 24 h, and flow cytometry was used to analyze the level of ROS in cells after DCFH-DA was added to stain the cells. Bar graphic representations of the fluorescence intensity upon different treatments relative to control were shown. Data was presented as . (b) SK-OV-3 cells were treated with control IgG (25 μg/mL), trastuzumab (25 μg/mL), brusatol (5 μM), or trastzumab (25 μg/mL) plus brusatol (5 μM), and flow cytometry was used to analyze the level of ROS in cells after DCFH-DA was added to stain the cells. Bar graphic representations of the fluorescence intensity upon different treatments relative to control were shown. Data was presented as .
(a)
(b)

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.